Toronto Dominion Bank
FATE icon

Toronto Dominion Bank’s Fate Therapeutics FATE Stock Holding History

Toronto Dominion Bank’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-850
Closed -$952 – 1978
2025
Q2 		$952 Buy
+850
New +$988 ﹤0.01% 1716

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wilshire Advisors Santa Monica, California $10.3M AUM 79.91% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Toronto Dominion Bank's FATE Position: Q3 2025 in Review

Toronto Dominion Bank sold out of Fate Therapeutics (FATE) in Q3 2025, closing a stake of 850 shares — an estimated $952 sold.

Toronto Dominion Bank first reported a position in FATE in Q2 2025 and held it in 1 quarter. The position peaked at $952 in Q2 2025. 143 funds tracked by Wall St. Rank hold FATE as of Q3 2025.

  • Toronto Dominion Bank reported no remaining Fate Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Toronto Dominion Bank sold 850 Fate Therapeutics shares in Q3 2025, an estimated $952.
  • Toronto Dominion Bank first reported a position in Fate Therapeutics in Q2 2025 and held it in 1 quarter.
  • Toronto Dominion Bank's Fate Therapeutics position peaked at $952 in Q2 2025.
  • 143 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2025.

Based on Toronto Dominion Bank's 13F filing for Q3 2025, filed 14 Nov 2025.